EAACI Guidelines on allergen immunotherapy: IgE-mediated food allergy
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
EAACI Guidelines on allergen immunotherapy : IgE-mediated food allergy. / Pajno, G. B.; Fernandez-Rivas, M.; Arasi, S.; Roberts, G.; Akdis, C. A.; Alvaro-Lozano, M.; Beyer, K.; Bindslev-Jensen, C.; Burks, W.; Ebisawa, M.; Eigenmann, P.; Knol, E.; Nadeau, K. C.; Poulsen, L. K.; van Ree, R.; Santos, A. F.; du Toit, G.; Dhami, S.; Nurmatov, U.; Boloh, Y.; Makela, M.; O'Mahony, L.; Papadopoulos, N.; Sackesen, C.; Agache, I.; Angier, E.; Halken, S.; Jutel, M.; Lau, S.; Pfaar, O.; Ryan, D.; Sturm, G.; Varga, E. M.; van Wijk, R. G.; Sheikh, A.; Muraro, A.
I: Allergy: European Journal of Allergy and Clinical Immunology, Bind 73, Nr. 4, 2018, s. 799-815.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - EAACI Guidelines on allergen immunotherapy
T2 - IgE-mediated food allergy
AU - Pajno, G. B.
AU - Fernandez-Rivas, M.
AU - Arasi, S.
AU - Roberts, G.
AU - Akdis, C. A.
AU - Alvaro-Lozano, M.
AU - Beyer, K.
AU - Bindslev-Jensen, C.
AU - Burks, W.
AU - Ebisawa, M.
AU - Eigenmann, P.
AU - Knol, E.
AU - Nadeau, K. C.
AU - Poulsen, L. K.
AU - van Ree, R.
AU - Santos, A. F.
AU - du Toit, G.
AU - Dhami, S.
AU - Nurmatov, U.
AU - Boloh, Y.
AU - Makela, M.
AU - O'Mahony, L.
AU - Papadopoulos, N.
AU - Sackesen, C.
AU - Agache, I.
AU - Angier, E.
AU - Halken, S.
AU - Jutel, M.
AU - Lau, S.
AU - Pfaar, O.
AU - Ryan, D.
AU - Sturm, G.
AU - Varga, E. M.
AU - van Wijk, R. G.
AU - Sheikh, A.
AU - Muraro, A.
N1 - This article also appears in: JM Must Read Articles - Allergy
PY - 2018
Y1 - 2018
N2 - Food allergy can result in considerable morbidity, impairment of quality of life, and healthcare expenditure. There is therefore interest in novel strategies for its treatment, particularly food allergen immunotherapy (FA-AIT) through the oral (OIT), sublingual (SLIT), or epicutaneous (EPIT) routes. This Guideline, prepared by the European Academy of Allergy and Clinical Immunology (EAACI) Task Force on Allergen Immunotherapy for IgE-mediated Food Allergy, aims to provide evidence-based recommendations for active treatment of IgE-mediated food allergy with FA-AIT. Immunotherapy relies on the delivery of gradually increasing doses of specific allergen to increase the threshold of reaction while on therapy (also known as desensitization) and ultimately to achieve post-discontinuation effectiveness (also known as tolerance or sustained unresponsiveness). Oral FA-AIT has most frequently been assessed: here, the allergen is either immediately swallowed (OIT) or held under the tongue for a period of time (SLIT). Overall, trials have found substantial benefit for patients undergoing either OIT or SLIT with respect to efficacy during treatment, particularly for cow's milk, hen's egg, and peanut allergies. A benefit post-discontinuation is also suggested, but not confirmed. Adverse events during FA-AIT have been frequently reported, but few subjects discontinue FA-AIT as a result of these. Taking into account the current evidence, FA-AIT should only be performed in research centers or in clinical centers with an extensive experience in FA-AIT. Patients and their families should be provided with information about the use of FA-AIT for IgE-mediated food allergy to allow them to make an informed decision about the therapy.
AB - Food allergy can result in considerable morbidity, impairment of quality of life, and healthcare expenditure. There is therefore interest in novel strategies for its treatment, particularly food allergen immunotherapy (FA-AIT) through the oral (OIT), sublingual (SLIT), or epicutaneous (EPIT) routes. This Guideline, prepared by the European Academy of Allergy and Clinical Immunology (EAACI) Task Force on Allergen Immunotherapy for IgE-mediated Food Allergy, aims to provide evidence-based recommendations for active treatment of IgE-mediated food allergy with FA-AIT. Immunotherapy relies on the delivery of gradually increasing doses of specific allergen to increase the threshold of reaction while on therapy (also known as desensitization) and ultimately to achieve post-discontinuation effectiveness (also known as tolerance or sustained unresponsiveness). Oral FA-AIT has most frequently been assessed: here, the allergen is either immediately swallowed (OIT) or held under the tongue for a period of time (SLIT). Overall, trials have found substantial benefit for patients undergoing either OIT or SLIT with respect to efficacy during treatment, particularly for cow's milk, hen's egg, and peanut allergies. A benefit post-discontinuation is also suggested, but not confirmed. Adverse events during FA-AIT have been frequently reported, but few subjects discontinue FA-AIT as a result of these. Taking into account the current evidence, FA-AIT should only be performed in research centers or in clinical centers with an extensive experience in FA-AIT. Patients and their families should be provided with information about the use of FA-AIT for IgE-mediated food allergy to allow them to make an informed decision about the therapy.
KW - Adolescent
KW - Adult
KW - Allergen immunotherapy
KW - Allergy
KW - Food
KW - Pediatric
U2 - 10.1111/all.13319
DO - 10.1111/all.13319
M3 - Journal article
C2 - 29205393
AN - SCOPUS:85038248175
VL - 73
SP - 799
EP - 815
JO - Allergy: European Journal of Allergy and Clinical Immunology
JF - Allergy: European Journal of Allergy and Clinical Immunology
SN - 0105-4538
IS - 4
ER -
ID: 189619012